Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
12/15/25 09:00 | 12/11/25 | MRNA | Health | BioPrd | Biological Products, (No Diag | Afeyan Noubar | MA | D | 2 | M.d | 963 | 20.19 | 0 | 48 | 1 | 6,856 | I | |||||||||||||||
12/15/25 09:00 | 12/11/25 | MRNA | Health | BioPrd | Biological Products, (No Diag | Afeyan Noubar | MA | D | 2 | S.d | -963 | 20.19 | 0 | -48 | 6,856 | I | ||||||||||||||||
12/15/25 08:59 | 12/11/25 | MRNA | Health | BioPrd | Biological Products, (No Diag | Bancel Stephane | MA | DO | CEO | 1 | M.d | 7,500 | 10.90 | 0 | 688 | 3 | 21,958 | D | ||||||||||||||
12/11/25 16:16 | 12/9/25 | MRNA | Health | BioPrd | Biological Products, (No Diag | Hussain Abbas | MA | D | 2 | S.d | -14 | 7.16 | 0 | -2 | 2 | D | ||||||||||||||||
12/8/25 16:44 | 12/5/25 | MRNA | Health | BioPrd | Biological Products, (No Diag | Mock James M | MA | O | CFO | 3 | M.dm | 0 | 0.00 | 0 | 50 | 43 | D | |||||||||||||||
12/8/25 16:40 | 12/5/25 | MRNA | Health | BioPrd | Biological Products, (No Diag | Klinger Shannon Thyme | MA | O | GC | 3 | M.dm | 0 | 0.00 | 0 | 49 | 999% | 53 | D | ||||||||||||||
12/2/25 16:44 | 12/1/25 | MRNA | Health | BioPrd | Biological Products, (No Diag | Hoge Stephen | MA | O | P | 2 | M.dm | 0 | 0.00 | 0 | 3 | 0 | 1,611 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |